Gilead Sciences Intrinsic Value Calculation – Investors in Gilead Sciences Reap 28% Return in Just One Year!
June 12, 2023
🌥️Trending News
Investors in Gilead Sciences ($NASDAQ:GILD) have been reaping the rewards over the past year with a 28% return on their investments! Gilead Sciences is a biopharmaceutical company based in California that focuses on developing treatments for serious and life-threatening conditions, such as HIV, hepatitis B and related liver diseases, and pulmonary hypertension. The company has been at the forefront of innovation, developing treatments and medications that have changed the lives of many individuals around the world.
Their commitment to innovation has translated into strong financial returns as evidenced by the impressive growth in their stock price. With a new focus on cancer therapy and immunology, investors can look forward to continued growth in the future.
Analysis – Gilead Sciences Intrinsic Value Calculation
At GoodWhale, we have conducted an in-depth analysis of GILEAD SCIENCES‘s fundamentals and have arrived at the conclusion that the intrinsic value of their share is around $71.4. This valuation is based on our proprietary Valuation Line which takes into account various factors such as market forces, financial performance, and industry trends. Currently, GILEAD SCIENCES shares are trading at $77.7 – a fair price that is overvalued by 8.8% compared to our estimated intrinsic value. As such, investors should take this into account before deciding to invest in the company. However, we believe that the company has strong fundamentals and could be a good long-term investment option for those looking to diversify their portfolios. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Gilead Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 27.04k | 5.58k | 32.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Gilead Sciences. More…
| Operations | Investing | Financing |
| 8.98k | -2.22k | -6.08k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 61.88k | 40.94k | 17.02 |
Key Ratios Snapshot
Some of the financial key ratios for Gilead Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.0% | 42.8% | 30.3% |
| FCF Margin | ROE | ROA |
| 31.4% | 24.1% | 8.3% |
Peers
In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.
– SCYNEXIS Inc ($NASDAQ:SCYX)
SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.
Summary
Investors in Gilead Sciences have seen an impressive return on their investment over the past year, with a 28% increase in stock prices. Gilead Sciences is a biopharmaceutical company that specializes in developing treatments for life-threatening diseases. The company has recently seen success in the development of new antiviral treatments for hepatitis C, HIV/AIDS, and other chronic infectious diseases. Gilead Sciences has also seen recent growth in its research and development capabilities, leading to promising new treatments in the pipeline.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
